China Medical System Holdings Limited (0867.HK)

7.380 +0.370 (+5.28%) At close: 04:08PM HKT

China Medical System Holdings Limited

Island Place Tower
Unit 2106 21st Floor 510 King’s Road
North Point
Hong Kong
852 2369 7678
https://web.cms.net.cn/zh/home/

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 5,701

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Kong Lam	Founder, Chairman, CEO & President	5.88M	N/A	1965
Ms. Yanling Chen	CFO, VP & Executive Director	4.78M	N/A	1970
Mr. Hongbing Chen	COO, VP, Director of Sales & Marketing and Executive Director	5.44M	N/A	1967
Ms. Sanyan Wu	Director of Legal Department & Company Secretary	N/A	N/A	1983
Dr. Huaizheng Peng M.D., Ph.D.	Chief Business Officer	N/A	N/A	1962
Mr. Fei Jiang	Chief Investment Officer of Greater China	N/A	N/A	N/A
Mr. James Patrick Stearns	Chief Investment Officer of Europe & America	N/A	N/A	1979

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis. The company also offers Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; ILUMETRI, a tildrakizumab injection to treat moderate-tosevere plaque psoriasis; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. In addition, it provides Aethoxysklerol for sclerotherapy of different varicose veins; Heling Soothing product for skin soothing; Vmonalisa for mid to deep dermal implantation; Neauvia Hyaluronic Acid series; EyeOP1 to treat glaucoma; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; MOVICOL for treating chronic constipation and faecal impaction; and MeteoSpasmyl to treat gastrointestinal flatulence and pain. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.

Corporate governance

China Medical System Holdings Limited’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 4; Board: 1; Shareholder rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.